Form 8-K OTONOMY, INC. For: Aug 30
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Otonomy (OTIC) PT Lowered to $9 at Cowen Amid Otividex Failure; Dramatic And Fast Changes Needed
August 30, 2017 10:44 AM EDTCowen analyst Ken Cacciatore lowered his price target on Otonomy (NASDAQ: OTIC) to $9.00 (from $55.00) while maintaining an Outperform rating following the Otividex failure.
Cacciatore said said the company will now need to make dramatic and rapid spending reductions and the focus... More
UPDATE: Otonomy (OTIC) Plunges Over 77% After Phase 3 Trial of OTIVIDEX Fails
August 30, 2017 7:33 AM EDT(Updated - August 30, 2017 7:37 AM EDT)
Otonomy (NASDAQ: OTIC) dropped 77% after shares resumed following a brief trading halt pending results for its AVERTS-1 Phase 3 clinical trial of OTIVIDEX in patients with Ménières disease. The clinical trial missed its primary endpoint.
... MoreOtonomy (OTIC) to Resume Trading at 7:30 AM ET
August 30, 2017 7:25 AM EDTOtonomy (NASDAQ: OTIC) to Resume Trading at 7:30 AM ET
... More